ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Notably, CML patients in stable molecular remission (MMR, MR4 or better) harbor BCR-ABL-positive residual disease [14–16•, 24, 25], but have a neglectable chance to develop TKI resistance or BCR-ABL kinase mutations.